Artificial intelligence is helping the world find new drug treatments. One of the leading companies is about to reach an important milestone and will enter the late-stage trial phase of drugs discovered by algorithms. Insilico Medicine, a company based in Hong Kong and New York, is using AI to develop a drug for an incurable lung disease called idiopathic pulmonary fibrosis.
We have noted that this drug is currently undergoing mid-term clinical trials in the United States and China, and preliminary results are expected to be available in early 2025. The trial has attracted significant attention from the drug industry because Insilico used AI to not only identify a new way to fight this deadly disease but also to develop a new molecule to treat it. The UK’s Deep Pharma Intelligence research institute pointed out that Insilico’s drug is the world’s first preclinical drug candidate discovered entirely by AI.
Alex Zhavoronkov, founder and CEO of Insilico, said Insilico was able to achieve its breakthrough because it “used AI to find a new target, discovered a molecule, and entered mid-stage clinical trials.” He said, If the company’s lung disease drug is successfully developed, “that would change everything.”
For more interesting article like this:- Free Android games, free Android apps, free softwares, Gadget Reviews, comparisons, troubleshooting guides, listicles, and tips & tricks related to Windows, Android, iOS, and macOS, follow us on Google News, Facebook, Instagram, Twitter, YouTube, and Pinterest.